FDA Calls for More Data on Dupilumab for CSU Indication FDA Calls for More Data on Dupilumab for CSU Indication

In a letter, the FDA stated that additional efficacy data are required to support an approval for chronic spontaneous urticaria (CSU), according to the manufacturers of dupilumab.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Dermatology News Source Type: news